Comparative Pharmacology
Head-to-head clinical analysis: OXSORALEN versus TRISORALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXSORALEN versus TRISORALEN.
OXSORALEN vs TRISORALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Psoralen intercalates into DNA and upon UVA exposure forms covalent crosslinks between pyrimidine bases, inhibiting DNA synthesis and cell proliferation.
Psoralen (trisoralen) intercalates into DNA and, upon UVA irradiation, forms covalent cross-links between pyrimidine bases, inhibiting DNA replication and cell division. It also suppresses DNA synthesis and epidermal cell proliferation.
0.6 mg/kg orally once daily, 2 hours before UV-A exposure, or 0.4 mg/kg orally 2 hours before psoralen plus UV-A (PUVA) therapy. For topical use, a 1% lotion is applied 2 hours prior to UV-A exposure.
10-70 mg orally 2 hours before UVA exposure, given 2-3 times per week, with dose based on body weight (0.6 mg/kg).
None Documented
None Documented
Approximately 2-5 hours for parent drug; clinical effect persists longer due to epidermal DNA binding.
Terminal elimination half-life is approximately 2 hours (range 1.1–2.5 h) for trioxsalen after oral administration; clinical phototoxic effect peaks at 2–4 hours post-dose.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the majority of metabolites, though exact percentage not well defined.
Primarily renal elimination of metabolites; less than 5% excreted unchanged in urine. Approximately 90% of a radiolabeled dose is recovered in urine within 24 hours, with less than 5% in feces.
Category C
Category C
Psoralen
Psoralen